• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

复发性骨肉瘤的管理问题综述

Review of management issues in relapsed osteosarcoma.

作者信息

Vijayamurugan Nataraj, Bakhshi Sameer

机构信息

Departments of Medical Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi-110029, India.

出版信息

Expert Rev Anticancer Ther. 2014 Feb;14(2):151-61. doi: 10.1586/14737140.2014.863453. Epub 2013 Nov 26.

DOI:10.1586/14737140.2014.863453
PMID:24308680
Abstract

Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. With combined modality treatment long-term survival rate for localized disease is near 70%. Thirty percent of patients relapse with lung as the commonest site. Surgery is the treatment of choice for relapsed patients whenever possible. Addition of chemotherapy to surgery provides survival benefit in patients not achieving second surgical remission. Even patients with multiple lung recurrences can be cured with repeated thoracotomies. Disease-free interval and complete surgical resection are the main prognostic factor for post-relapse survival.

摘要

骨肉瘤是儿童和青少年中最常见的原发性恶性骨肿瘤。采用综合治疗,局限性疾病的长期生存率接近70%。30%的患者会复发,最常见的复发部位是肺部。只要有可能,手术是复发患者的首选治疗方法。对于未实现第二次手术缓解的患者,手术加化疗可提高生存率。即使是有多次肺部复发的患者,通过反复开胸手术也可治愈。无病间期和完全手术切除是复发后生存的主要预后因素。

相似文献

1
Review of management issues in relapsed osteosarcoma.复发性骨肉瘤的管理问题综述
Expert Rev Anticancer Ther. 2014 Feb;14(2):151-61. doi: 10.1586/14737140.2014.863453. Epub 2013 Nov 26.
2
[Prognostic factors for the local recurrence of osteosarcoma in extremities treated with combined therapy].[肢体骨肉瘤联合治疗后局部复发的预后因素]
Zhonghua Wai Ke Za Zhi. 2007 Aug 15;45(16):1114-7.
3
Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience.诊断时的转移性骨肉瘤:预后因素及长期结局——法国儿科经验
Cancer. 2005 Sep 1;104(5):1100-9. doi: 10.1002/cncr.21263.
4
Treatment algorithm for locally recurrent osteosarcoma based on local disease-free interval and the presence of lung metastasis.基于局部无病生存期和肺转移情况的局部复发性骨肉瘤治疗算法
Cancer. 2006 Oct 1;107(7):1607-16. doi: 10.1002/cncr.22197.
5
Metastatic osteosarcoma: a challenging multidisciplinary treatment.转移性骨肉瘤:一种具有挑战性的多学科治疗方法。
Expert Rev Anticancer Ther. 2016 May;16(5):543-56. doi: 10.1586/14737140.2016.1168697. Epub 2016 Apr 6.
6
Osteosarcoma in the first decade of life.十岁前的骨肉瘤。
Med Pediatr Oncol. 2003 Nov;41(5):480-3. doi: 10.1002/mpo.10403.
7
Multiple relapses in high-grade osteosarcoma: when to stop aggressive therapy?高级别骨肉瘤的多次复发:何时停止激进治疗?
Pediatr Blood Cancer. 2015 Mar;62(3):529-30. doi: 10.1002/pbc.25360. Epub 2014 Dec 8.
8
Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS).综合治疗后骨肉瘤复发:对骨肉瘤协作研究组(COSS)中未经挑选患者的分析。
J Clin Oncol. 2005 Jan 20;23(3):559-68. doi: 10.1200/JCO.2005.04.063.
9
Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery?骨肉瘤患者仅通过化疗和取消手术就能治愈吗?
Cancer. 2002 Nov 15;95(10):2202-10. doi: 10.1002/cncr.10944.
10
Influence of local recurrence on survival in patients with extremity osteosarcoma treated with neoadjuvant chemotherapy: the experience of a single institution with 44 patients.局部复发对接受新辅助化疗的肢体骨肉瘤患者生存的影响:一家机构对44例患者的经验。
Cancer. 2006 Jun 15;106(12):2701-6. doi: 10.1002/cncr.21937.

引用本文的文献

1
Metachronous Osteosarcoma, A Differential Diagnosis to be Considered in Children With Osteosarcoma: A Review of Literature and a Case From Our Center.同时性骨肉瘤,骨肉瘤患儿需要考虑的鉴别诊断:文献复习及来自本中心的 1 例病例报告。
J Pediatr Hematol Oncol. 2023 Apr 1;45(3):105-110. doi: 10.1097/MPH.0000000000002560. Epub 2022 Oct 17.
2
Double Endoprosthesis in the Management of Refractory Metastatic Primary Bone Tumors in Children and Young Adults.双关节假体在儿童和青年难治性转移性原发性骨肿瘤治疗中的应用
Adv Orthop. 2021 Jul 23;2021:9944702. doi: 10.1155/2021/9944702. eCollection 2021.
3
Receptor tyrosine kinase inhibitors for the treatment of osteosarcoma and Ewing sarcoma.
受体酪氨酸激酶抑制剂在骨肉瘤和尤文肉瘤治疗中的应用。
Pediatr Blood Cancer. 2021 Aug;68(8):e29084. doi: 10.1002/pbc.29084. Epub 2021 Apr 24.
4
LncRNA SNHG15 regulates osteosarcoma progression and via sponging miR-346 and regulating TRAF4 expression.长链非编码RNA SNHG15通过吸附miR-346并调节TRAF4表达来调控骨肉瘤进展。
Open Life Sci. 2020 Jul 3;15(1):423-436. doi: 10.1515/biol-2020-0039. eCollection 2020.
5
PRRX1 promotes malignant properties in human osteosarcoma.PRRX1促进人类骨肉瘤的恶性特性。
Transl Oncol. 2021 Jan;14(1):100960. doi: 10.1016/j.tranon.2020.100960. Epub 2020 Dec 9.
6
SP1-Induced Upregulation of lncRNA LINC00514 Promotes Tumor Proliferation and Metastasis in Osteosarcoma by Regulating miR-708.SP1诱导的lncRNA LINC00514上调通过调控miR-708促进骨肉瘤肿瘤增殖和转移。
Cancer Manag Res. 2020 May 11;12:3311-3322. doi: 10.2147/CMAR.S242464. eCollection 2020.
7
Target therapy of TRIM-14 inhibits osteosarcoma aggressiveness through the nuclear factor-κB signaling pathway.TRIM-14的靶向治疗通过核因子κB信号通路抑制骨肉瘤的侵袭性。
Exp Ther Med. 2018 Mar;15(3):2365-2373. doi: 10.3892/etm.2017.5679. Epub 2017 Dec 27.
8
Baicalein inhibits progression of osteosarcoma cells through inactivation of the Wnt/β-catenin signaling pathway.黄芩素通过使Wnt/β-连环蛋白信号通路失活来抑制骨肉瘤细胞的进展。
Oncotarget. 2017 Sep 18;8(49):86098-86116. doi: 10.18632/oncotarget.20987. eCollection 2017 Oct 17.
9
Antisense lncRNA FOXF1-AS1 Promotes Migration and Invasion of Osteosarcoma Cells Through the FOXF1/MMP-2/-9 Pathway.反义长链非编码 RNA FOXF1-AS1 通过 FOXF1/MMP-2/-9 通路促进骨肉瘤细胞的迁移和侵袭。
Int J Biol Sci. 2017 Sep 5;13(9):1180-1191. doi: 10.7150/ijbs.21722. eCollection 2017.
10
Associations of chemo- and radio-resistant phenotypes with the gap junction, adhesion and extracellular matrix in a three-dimensional culture model of soft sarcoma.在软组织肉瘤三维培养模型中,化疗和放疗抗性表型与间隙连接、黏附及细胞外基质的关联
J Exp Clin Cancer Res. 2015 Jun 10;34(1):58. doi: 10.1186/s13046-015-0175-0.